Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans.

摘要: We explored the effects of recombinant human leptin (rL) as an adjunct mild energy restriction (2092 kJ/day less than needed) in treatment obese humans part a larger multicentre trial. In double blind, randomised, placebo (P)-controlled design, 10 mg rL once daily vs twice (rL OD/BID, by s.c. injection) upon body weight, resting expenditure (REE) and intake were compared. The study groups comprised 9 (P), 15 OD) 6 BID) healthy subjects (body mass index 27.5-35 kg/m2). observed both treated with decline weight. [2.8+/-1.1 kg 5.2+/-0.9 OD), 7.9+/-1.4 BID), p < 0.035]. No significant or REE observed. However, tended to reduce associated restriction, whereas tendency increase back baseline levels placebo-treated was largely prevented rL. Thus, appears enhance loss weight dose-dependent fashion if prescribed restriction. This effect might be mediated ability counteract behavioural metabolic adaptations that accompany attempts.